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Alexander R. van Rosendael, MD,a,b Leslee J. Shaw, PHD,c Joe X. Xie, MD,c Aukelien C. Dimitriu-Leen, MD,a
Jeff M. Smit, MD,a Arthur J. Scholte, MD, PHD,a Jacob M. van Werkhoven, MD, PHD,a Tracy Q. Callister, MD,d
Augustin DeLago, MD,e Daniel S. Berman, MD,f Martin Hadamitzky, MD,g Jeorg Hausleiter, MD,g
Mouaz H. Al-Mallah, MD,h Matthew J. Budoff, MD,i Philipp A. Kaufmann, MD,j Gilbert Raff, MD,k
Kavitha Chinnaiyan, MD,k Filippo Cademartiri, MD, PHD,l Erica Maffei, MD,m Todd C. Villines, MD,n
Yong-Jin Kim, MD,o Gudrun Feuchtner, MD,p Fay Y. Lin, MD,b Erica C. Jones, MD,b Gianluca Pontone, MD, PHD,q
Daniele Andreini, MD, PHD,q Hugo Marques, MD,r Ronen Rubinshtein, MD,s Stephan Achenbach, MD,t
Allison Dunning, MD,u Millie Gomez, MD,b Niree Hindoyan, BS,b Heidi Gransar, MD,f Jonathon Leipsic, MD, PHD,v
Jagat Narula, MD, PHD,w James K. Min, MD,b Jeroen J. Bax, MD, PHDaABSTRACTISSOBJECTIVES This study was designed to assess the prognostic value of a new comprehensive coronary computed
tomography angiography (CTA) score compared with the stenosis severity component of the Coronary Artery
Disease-Reporting and Data System (CAD-RADS).
BACKGROUND Current risk assessment with coronary CTA is mainly focused on maximal stenosis severity.
Integration of plaque extent, location, and composition in a comprehensive model may improve risk stratiﬁcation.
METHODS A total of 2,134 patients with suspected but without known CAD were included. The predictive value of
the comprehensive CTA score (ranging from 0 to 42 and divided into 3 groups: 0 to 5, 6 to 20, and >20) was compared
with the CAD-RADS combined into 3 groups (0% to 30%, 30% to 70% and $70% stenosis). Its predictive
performance was internally and externally validated (using the 5-year follow-up dataset of the CONFIRM [Coronary
CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry], n ¼ 1,971).
RESULTS The mean age of patients was 55  13 years, mean follow-up 3.6  2.8 years, and 130 events (myocardial
infarction or death) occurred. The new, comprehensive CTA score showed strong and independent predictive value using
the Cox proportional hazard analysis. A model including clinical variables plus comprehensive CTA score showed better
discrimination of events compared with a model consisting of clinical variables plus CAD-RADS (0.768 vs. 0.742,
p ¼ 0.001). Also, the comprehensive CTA score correctly reclassiﬁed a signiﬁcant proportion of patients compared
with the CAD-RADS (net reclassiﬁcation improvement 12.4%, p < 0.001). Good predictive accuracy was reproduced in
the external validation cohort.
CONCLUSIONS The new comprehensive CTA score provides better discrimination and reclassiﬁcation of events
compared with the CAD-RADS score based on stenosis severity only. The score retained similar prognostic accuracy when
externally validated. Anatomic risk scores can be improved with the addition of extent, location, and compositional mea-
sures of atherosclerotic plaque. (Comprehensive CTA risk score calculator is available at: http://18.224.14.19/calcApp/)
(J Am Coll Cardiol Img 2019;12:1987–97) © 2019 by the American College of Cardiology Foundation.N 1936-878X/$36.00 https://doi.org/10.1016/j.jcmg.2018.10.024
ABBR EV I A T I ON S
AND ACRONYMS
BMI = body mass index
CAD = coronary artery disease
CAD-RADS = Coronary Artery
Disease–Reporting and Data
System
CI = conﬁdence interval
CTA = computed tomography
angiography
HR = hazard ratio
NRI = net reclassiﬁcation
improvement
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1988C oronary computed tomographyangiography (CTA) provides directnoninvasive anatomical assessment
of the coronary arteries and has a high diag-
nostic accuracy for detection and exclusion
of obstructive coronary artery disease (CAD)
($50% stenosis) compared with invasive cor-
onary angiography (1). Coronary CTA also
provides prognostic information for predic-
tion of future cardiovascular events (2,3).
Several studies have shown that obstructive
CAD on coronary CTA is associated with
worse outcomes compared to nonobstructiveor no CAD (4–6). Current coronary CTA reading is
guided by the Coronary Artery Disease – ReportingSEE PAGE 1998and Data system (CAD-RADS), which is mainly based
on maximal stenosis severity. However, other coro-
nary plaque characteristics including plaque extent,
location, and composition carry prognostic value
(2,7,8). The location of coronary plaque (proximal
versus distal), the number of plaques, and plaque
composition (noncalciﬁed or mixed versus calciﬁed
lesions) have all been associated with clinical out-
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pose of the current study was to determine whether
a new comprehensive risk score may provide incre-
mental prognostic value over the stenosis severity
component of the CAD-RADS score.
METHODS
STUDY POPULATION. Derivation cohort from Leiden,
the Netherlands. The primary study cohort to derive
the novel risk score included a consecutive series
of 2,809 stable patients with suspected or known
CAD who were clinically referred for coronary CTA
at the Leiden University Medical Center (LUMC),
the Netherlands, between 2005 and 2015. Exclusion
criteria for coronary CTA were cardiac arrhythmias,
known hypersensitivity to iodine contrast media,
or pregnancy. Patients with an uninterpretable
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19892,134 patients in the derivation cohort. Cardiovascu-
lar risk factors consisted of diabetes mellitus (deﬁned
as a fasting glucose $126 mg/dl or the use of insulin/
oral hypoglycemic agents), hypertension (systolic
blood pressure$140mmHgor diastolic blood pressure
$90 mm Hg or the use of antihypertensive medica-
tion), hypercholesterolemia (serum total cholesterol
$230 mg/dl or serum triglycerides $200 mg/dl or
treatment with lipid-lowering drugs), family history of
CAD (presence of CAD in ﬁrst-degree family members
at <55 years of age in men and <65 years of age in
women), and currently smoking. Chest pain typicality
was categorized as nonanginal, atypical, and typical
chest pain.
Demographic and clinical data were prospectively
collected from the departmental electronic informa-
tion system (EPD-Vision, LUMC). The LUMC Institu-
tional Review Board approved this evaluation of
clinically acquired data and waived the need for
patient written informed consent.
External validation cohort, CONFIRM Registry. The
comprehensive CTA score was tested in an external
validation cohort (details described below) using
the CONFIRM (Coronary CT angiography Evaluation
for Clinical Outcomes: An International Multicenter)
registry; a dynamic, international, multicenter,
observational cohort study that prospectively
collected clinical and follow-up data of patients un-
dergoing $64-slice coronary CTA; the rationale and
design of CONFIRM have been previously described
(11). In brief, this cohort comprised 12,086 patients
with 5-year follow-up data among 17 centers in
9 countries between 2002 and 2009 (12). Patients
with missing coronary system dominance or plaque
composition data (n ¼ 5,553); missing follow-up data
regarding MI (n ¼ 3,763); and previous percutaneous
intervention, coronary artery bypass surgery, or MI
(n ¼ 799) were excluded. In total, 1,971 patients were
included in the CONFIRM external validation cohort.
Institutional review board approval was received for
each study site and each patient provided written
informed consent.
CTA ACQUISITION AND IMAGE ANALYSIS. For the
derivation cohort (Leiden, the Netherlands), patients
were scanned using a 64-slice CT scanner (Aquil-
lion64, Toshiba Medical Systems, Otawara, Tochigi,
Japan) or a 320-slice CT scanner (Toshiba Multi-slice
Aquilion ONE System, Toshiba Medical Systems).
Before the examination, the patient’s heart rate
and blood pressure were monitored. In the absence
of contraindications, patients with a heart rate
exceeding 60 beats/min were administeredbeta-blocking medication (50 to 150 mg oral meto-
prolol, with an additional intravenous dose up to
15 mg if needed). Furthermore, sublingual nitroglyc-
erine (0.4 mg) was administered before scanning. All
scan parameters have been previously published (13).
Post-processing of the coronary CTA examinations
was performed with dedicated software (Vitrea2
and VitreaFx, Vital Images, Minnetonka, Minnesota).
Coronary anatomy was assessed using a 17-segment
model according to a modiﬁed American Heart
Association classiﬁcation (14). Stenosis severity
was visually assessed for each coronary plaque and
categorized as: normal, <30%, 30% to 50%, 50% to
70%, 70% to 99%, and occluded (7). In addition,
plaque composition was determined in all diseased
segments and graded as noncalciﬁed plaque (plaques
having lower density compared with the contrast-
enhanced lumen), calciﬁed plaque (plaques with
high density), and mixed plaque (containing ele-
ments of both noncalciﬁed and calciﬁed plaque). The
CTA examinations were interpreted by 2 physicians
highly experienced in CTA reading as previously
described (13). Image analysis from the external
validation cohort was uniformly performed at each
site in accordance with the computed tomography
(CT) guidelines, as previously described (11).
CAD-RADS. The CAD-RADS categories are based on
the highest grade coronary stenosis per patient and
are deﬁned as follows: CAD-RADS 0 ¼ no coronary
plaque, CAD-RADS 1 ¼ 1% to 24% stenosis or present
coronary plaque without stenosis, CAD-RADS 2 ¼ 25%
to 49% stenosis, CAD-RADS 3 ¼ 50% to 69% stenosis,
CAD-RADS 4a ¼ 70% to 99% stenosis in 1 or 2 coronary
arteries, CAD-RADS 4b ¼ 70% to 99% stenosis in
3 coronary arteries or $50% stenosis in the left
main, CAD-RADS 5 ¼ occlusion. According to these
deﬁnitions, patients in the present analysis were
categorized in their appropriate CAD-RADS group,
where a stenosis <30% was considered equal to 1%
to 24% and 30% to 49% was considered equal to 25%
to 49%. The CAD-RADS classiﬁcation also includes
the presence of vulnerable high-risk plaque, howev-
er, this information was not included in the present
study because the high-risk plaque features were
not systematically assessed. To allow for compari-
sons with the comprehensive CTA score, the several
CAD-RADS categories were merged into 3 groups:
group 1 ¼ CAD-RADS 0 or 1 (no to minimal CAD),
group 2 ¼ CAD-RADS 2 or 3 (moderate CAD), and
group 3 ¼ CAD-RADS 4 or 5 (severe CAD).
COMPREHENSIVE CTA SCORE. A comprehensive CTA
score incorporating the presence, extent, severity,
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1990location, and composition of CAD was constructed
based on the following:
1. A 17-segment model of the coronary artery tree
based on American Heart Association criteria (14).
2. Previous literature describing the individual pre-
dictive value of plaque extent, severity, and
composition variables as observed on coronary
CTA (2,3,7,9).
3. The Leaman score which provides weight factors
for plaque location (15).
Regarding the presence and extent of CAD on
coronary CTA, several studies have shown that the
number of segments with CAD is associated with
increased risk for events (2,3,5,6). When stratifying
the diseased segments according to plaque composi-
tion, van Werkhoven et al. (7) observed a hazard ratio
(HR) of 1.1 for segments with calciﬁed plaque, 1.2 for
segments with noncalciﬁed plaque, and 1.3 for seg-
ments with mixed plaques. Based on these ﬁndings,
the weight factor for the presence, extent, and
composition of plaque in the score are 1.1, 1.2, or 1.3,
respectively, for calciﬁed, noncalciﬁed, or mixed
plaque. In addition to plaque presence, extent, and
composition, stenosis severity is also an important
predictor for future events. In the comprehensive
CTA score the weight factor for stenosis severity was
based on the previously observed HR of 1.4 (95% CI:
1.2 to 1.6) for the number of segments with obstruc-
tive stenosis (7). Finally, lesions in more proximal
coronary artery segments are known to convey a
higher risk for cardiovascular events, possibly due to
the larger volume of affected myocardium in case of a
coronary occlusion (5). As a result, plaque location
was integrated into the comprehensive CTA score
using the Leaman score, which places weights on
each segment’s relative contribution to the total left
ventricular blood ﬂow (15).
Altogether, the comprehensive CTA score is
calculated using the following approach. First, the
presence of CAD is determined in each segment.
When plaque is absent the score is 0. When plaque is
present a score of 1.1, 1.2, or 1.3 is given according to
plaque composition (calciﬁed, noncalciﬁed, and
mixed plaque, respectively). Subsequently, this
score is multiplied by a weight factor for the location
of the segment in the coronary artery tree (0.5
through 6 according to vessel, proximal location,
and system dominance), and multiplied by a weight
factor for stenosis severity (1.4 for $50% stenosis
and 1.0 for stenosis <50%). The ﬁnal score (range
0 to 42) is calculated by addition of the individual
segment scores (Figure 1). An online calculator is
available (16).FOLLOW-UP AND STUDY ENDPOINTS. For the deri-
vation cohort (Leiden, the Netherlands), mortality
data were retrieved from the municipal civil registry
of the Netherlands; and MI was assessed by clinical
visit report review or standardized telephone in-
terviews with conﬁrmation from medical ﬁle data.
The average follow-up time was 3.6  2.8 years. For
the external validation cohort (the CONFIRM regis-
try), death was ascertained by a query of the national
death index for U.S. sites and by direct interview or
telephone contact with the patient’s family, primary
physician, or review of the medical charts for non-
U.S. sites; and MI was ascertained by direct inter-
view, telephone contact (and conﬁrmed from the
medical ﬁles), or medical record review. The primary
endpoint was all-cause mortality or nonfatal MI
(deﬁned according to the standard deﬁnitions)
(17,18). Patients were followed for a mean of 5.2 
1.7 years.
STATISTICAL ANALYSIS. Continuous variables were
presented as mean  SD or median (25% to 75%
interquartile range), according to the distribution.
Categorical variables were presented as a number and
percent. Event-free survival was estimated using the
Kaplan-Meier method and the log-rank test was used
to compare the event-free survival distributions of
the groups within each score. The 2 scores were
available for all patients; <1.5% of data was missing
regarding cardiovascular risk factors or medication
use. The univariable and multivariable HRs with 95%
conﬁdence intervals (CIs) were generated by Cox
proportional hazard regression analysis. In each case,
the proportional hazards assumption was met. Model
overﬁtting was avoided by limiting multivariable
models to 1 variable for every 10 clinical outcomes.
Two multivariable models were created including
clinical characteristics (age, sex, hypertension, hy-
percholesterolemia, diabetes mellitus, smoking, and
family history of CAD) together with the CAD-RADS
(model 1) or the comprehensive CTA score (model
2). The discriminatory ability of several models was
assessed using receiver operating characteristics
curve analysis and compared with the DeLong
method (19). The incremental value of the compre-
hensive CTA score compared with the CAD-RADS was
assessed using the net reclassiﬁcation improvement
(NRI) statistic based on the methods developed by
Pencina et al. (20). The 5-year predicted risk cate-
gories were deﬁned as 0% to 3%, 3% to 10%, and
>10%. These speciﬁc risk thresholds were previously
described by Polonsky et al. (21). The use of different
cutoff values had minimal effect on the NRI (<0.5%
change). The 3 comprehensive CTA score groups were
deﬁned using scores of: 0 to 5, 6 to 20, and >20, as
FIGURE 1 Comprehensive CTA Score Calculation
RCA
Location Weight Factor
Segment (n) score =
Plaque Weight Factor
x
Stenosis Weight Factor
x
Location Weight Factor
Comprehensive / Leiden CTA risk score = Σ Segment (1-17) score
1 Prox RCA
2 Mid RCA
16 R-PL
4 R-PDA
3 Dist RCA
13 Dist LCx
11 Prox LCx
5 LM
Segment
LM
Prox LAD
Mid LAD
Dist LAD
D1
D2
Prox LCx
Dist LCx
AL/IM
OM
L-PL
L-PDA
Prox RCA
Mid RCA
Dist RCA
R-PL
R-PDA
Right Dominant
5
3.5
2.5
1
1
0.5
1.5
1
1
1
0.5
0
1
1
1
0.5
1
Left Dominant
6
3.5
2.5
1
1
0.5
2.5
1.5
1
1
0.5
1
0
0
0
0
0
Plaque Weight Factor
No Plaque
Calcified
Non-Calcified
Mixed
0
1.1
1.2
1.3
Stenosis Weight Factor
<50%
≥50%
1
1.4
6 Prox LAD
7 Mid LAD
9 D1
10 D2
8 Dist LAD
14 L-PL
12 OM
17 IM/AL
15 L-PDA
LCA
The new, comprehensive CTA score is calculated by addition of the individual segment
scores, which are obtained by multiplication of the plaque weight factor, the stenosis
weight factor, and the location weight factor. For example, a patient with a right
dominant system with a noncalciﬁed plaque with >50% stenosis in the middle RCA, and
a mixed plaque with <50% stenosis in the proximal LAD has the following score:
Segment 2 score (1.2  1.4  1 ¼ 1.68) þ Segment 6 score (1.3  1  3.5 ¼ 4.55) þ other
segments score (0) ¼ 6.23. Comprehensive CTA risk score calculator is available at:
http://18.224.14.19/calcApp/. AL ¼ anterolateral segment; CTA ¼ computed
tomography angiography; D1 ¼ diagonal 1; D2 ¼ diagonal 2; IM ¼ intermediate
segment; LAD ¼ left anterior descending coronary artery; LCA ¼ left coronary artery;
LCx ¼ left circumﬂex coronary artery; LM ¼ left main segment; L-PDA ¼ left posterior
descending artery; L-PL ¼ left posterolateral segment; OM ¼ obtuse marginal segment;
RCA ¼ right coronary artery; R-PDA ¼ right posterior descending artery; R-PL ¼ right
posterolateral segment.
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1991these values revealed the best discriminatory value.
For modeling of the comprehensive CTA score, in-
ternal validation was performed with bootstrapping
analysis using 1,000 replicates and using a 70:30
random split of the derivation cohort for the training
and validation cohorts, respectively. Then, this model
was externally validated using data from the inde-
pendent CONFIRM registry. All statistical analyses
were 2-sided and p < 0.05 was considered statistically
signiﬁcant. The analyses were performed using SAS
version 9.4 (SAS, Cary, North Carolina) and SPSS
version 24 (IBM, Armonk, New York).
RESULTS
CONVENTIONAL AND NEW COMPREHENSIVE CTA
SCORE. In total, 1,150 (53.9%) patients had CAD-
RADS 0 to 1, 867 (40.6%) patients had CAD-RADS 2
to 3, and 117 patients (5.5%) had CAD-RADS 4 to 5 in
the derivation cohort. Only 18 (2%) patients in the
CAD-RADS 0 to 1 group had >2 segments with plaque.
According to the comprehensive CTA score, 1,274
(59.7%) patients had the lowest score (0 to 5), 725
(34.0%) patients had a score of 6 to 20, and 135 (6.3%)
had the highest risk score category (>20). A mean
score of 6.37  3.85 was observed, ranging from 0 to
42. The primary endpoint occurred in 130 patients of
the derivation cohort. Events occurred in 22 patients
with CAD-RADS 0 to 1 (2.5%), in 93 patients with CAD-
RADS 2 to 3 (8.1%), and in 15 patients with CAD-RADS
4 to 5 (12.8%). Events occurred in 33 patients with
score 0 to 5 (2.6%), in 67 with score 6 to 20 (9.2%) and
in 30 with score >20 (22.2%).
BASELINE CHARACTERISTICS ACCORDING TO RISK
SCORE CATEGORIES. Table 1 presents the baseline
characteristics of the derivation cohort compared
with the external validation cohort across the 3
comprehensive CTA score categories (0 to 5, 6 to 20,
and >20). The mean patient’s age was consistently
lower in the derivation cohort compared with the
external validation cohort. Moreover, in the deriva-
tion cohort fewer patients were men, and the preva-
lence of hypertension, hypercholesterolemia, or
smoking was lower; conversely, diabetes mellitus was
more prevalent in the derivation cohort.
PROGNOSTIC PERFORMANCE OF THE NOVEL
COMPREHENSIVE CTA SCORE. Table 2 shows the
univariable and multivariable clinical and CTA Cox
regression models. For the CAD-RADS, univariable
HR for CAD-RADS 2 to 3 was 3.19 (95% CI: 2.00 to 5.07,
p < 0.001) and for CAD-RADS 4 to 5 the HR was
6.28 (95% CI: 3.26 to 12.11, p < 0.001), with CAD-RADS
0 to 1 as reference group. A strong association withevents was also observed using the comprehensive
CTA score categories: the HR of a score of 6 to 20 was
3.71 (95% CI: 2.44 to 5.62, p < 0.001) and the HR of a
score >20 was 8.00 (95% CI: 4.88 to 13.13, p < 0.001)
with a score of 0 to 5 as the reference group. A similar
pattern was observed after adjusting for clinical
characteristics (Table 2). The event-free survival
curves are presented in Figure 2. In both approaches,
a dose-dependent relationship is observed between
the degree of CAD and worse event-free survival. For
the CAD-RADS, event-free survival rates ranged from
TABLE 1 Patient Characteristics
Comprehensive CTA Score 0-5 Comprehensive CTA Score 5-20 Comprehensive CTA Score >20
Derivation Cohort
(n ¼ 1,274)
External Cohort
(n ¼ 1,096) p Value
Derivation Cohort
(n ¼ 725)
External Cohort
(n ¼ 746) p Value
Derivation Cohort
(n ¼ 135)
External Cohort
(n ¼ 129) p Value
Age, yrs 50.9  12.4 58.2  12.2 <0.001 59.9  10.5 64.6  10.0 <0.001 63.0  9.8 67.0  8.0 <0.001
BMI, kg/m2 26.6  5.0 26.8  4.4 0.287 26.9  4.4 27.0  4.1 0.836 27.2  4.9 27.2  3.7 0.950
Male 559 (44) 603 (55) <0.001 392 (54) 548 (74) <0.001 95 (70) 102 (79) 0.104
Chest pain symptoms <0.001 <0.001 0.071
Asymptomatic 504 (40) 466 (44) 304 (42) 319 (44) 61 (45) 41 (32)
Noncardiac 214 (17) 177 (17) 92 (13) 96 (13) 13 (10) 16 (13)
Atypical angina 466 (37) 306 (29) 248 (34) 178 (25) 38 (28) 35 (27)
Typical angina 89 (7) 119 (11) 81 (11) 133 (18) 23 (17) 36 (28)
Cardiovascular risk factors
Diabetes mellitus 270 (21) 88 (8) <0.001 235 (32) 112 (15) <0.001 64 (47) 43 (33) 0.020
Hypertension 441 (35) 572 (52) <0.001 398 (55) 504 (68) <0.001 90 (67) 96 (75) 0.138
Hypercholesterolemia 296 (23) 507 (46) <0.001 261 (36) 477 (64) <0.001 66 (49) 92 (72) <0.001
Family history of CAD 508 (40) 343 (32) <0.001 292 (40) 263 (35) 0.049 53 (39) 44 (34) 0.412
Currently smoking 206 (16) 241 (22) <0.001 120 (17) 223 (30) <0.001 42 (31) 47 (37) 0.337
Cardiovascular medication
Beta-blocker 359 (29) 181 (17) <0.001 282 (39) 179 (24) <0.001 46 (35) 28 (22) 0.028
ACE-I 181 (15) 155 (14) 0.868 190 (27) 163 (22) 0.053 49 (37) 34 (27) 0.074
Statin 313 (25) 260 (24) 0.486 305 (43) 329 (45) 0.432 71 (53) 76 (60) 0.294
Calcium antagonist 104 (8) 63 (7) 0.110 90 (13) 68 (11) 0.413 25 (19) 15 (14) 0.339
Aspirin 237 (19) 198 (18) 0.626 191 (27) 237 (32) 0.022 50 (38) 40 (32) 0.302
Values are mean  SD or n (%).
ACE-I ¼ angiotensin converting enzyme-inhibitor; BMI ¼ body mass index; CAD ¼ coronary artery disease; CTA ¼ computed tomography angiography.
TABLE 2 Univariable and Multivariable Cox Regression on the Derivation Cohort
Univariable Multivariable Model 1 Multivariable Model 2
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
Age, yrs 1.07 (1.05–1.08) <0.001 1.06 (1.04–1.08) <0.001 1.05 (1.03–1.07) <0.001
BMI, kg/m2 1.01 (0.97–1.05) 0.734
Male 1.17 (0.83–1.65) 0.369 1.09 (0.76–1.57) 0.622 0.98 (0.68–1.40) 0.902
Chest pain symptoms* 0.134
Noncardiac 0.48 (0.56–0.90) —
Atypical 0.89 (0.60–1.31) —
Typical 1.04 (0.60–1.79) —
Cardiovascular risk factors
Diabetes mellitus 1.44 (1.01–2.06) 0.046 1.39 (0.85–2.03) 0.086 1.27 (0.88–1.88) 0.193
Hypertension 1.46 (1.03–2.06) 0.033 0.98 (0.68–1.42) 0.928 0.94 (0.65–1.35) 0.722
Hypercholesterolemia 0.80 (0.55–1.18) 0.263 0.62 (0.41–0.92) 0.019 0.59 (0.39–0.89) 0.011
Family history of CAD 0.55 (0.38–0.81) 0.002 0.78 (0.46–1.01) 0.054 0.66 (0.45–0.98) 0.038
Currently smoking 1.70 (1.15–2.50) 0.008 2.01 (1.39–3.13) <0.001 1.90 (1.26–2.86) 0.002
CAD-RADS†
CAD-RADS 2-3 3.19 (2.00–5.07) <0.001 1.95 (1.19–3.20) 0.008 —
CAD-RADS 4-5 6.28 (3.26–12.11) <0.001 2.68 (1.30–5.53) 0.007 —
Comprehensive CTA score‡
6-20 3.71 (2.44–5.62) <0.001 — 2.69 (1.72–4.22) <0.001
>20 8.00 (4.88–13.13) <0.001 — 4.64 (2.63–8.16) <0.001
*Asymptomatic is the reference. †CAD-RADS 0-1 is the reference. ‡Comprehensive CTA score 0-5 is the reference.
CAD-RADS ¼ Coronary Artery Disease – Reporting and Data System; CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviation as in Table 1.
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FIGURE 2 Event-Free Survival for the CAD-RADS and the Comprehensive CTA Score
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Both classiﬁcations were associated with increased risk for events (death and myocardial infarction) over time. CAD ¼ coronary artery disease; RADS ¼ reporting and
data system; other abbreviation as in Figure 1.
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199394.4% for CAD-RADS 0 to 1, 80.5% for CAD-RADS 2 to
3, and 63.8% for CAD-RADS 4 to 5 (p < 0.001). By
comparison, the event-free survival rate for a compre-
hensive CTA score of 0 to 5 was 93.6%, 77.6% for a
score of 6 to 20, and 59.8% for a score >20 (p < 0.001).
The concordance index (c-index) of a model con-
taining clinical variables (age, sex, hypertension, hy-
percholesterolemia, diabetes mellitus, smoking, and
family history of CAD) was 0.727. Adding the CAD-
RADS increased the c-index to 0.742. A model con-
sisting of clinical variables plus the comprehensive
CTA score performed signiﬁcantly better (c-index
0.768 [95% CI: 0.725 to 0.811], p ¼ 0.001) compared
with a model including clinical variables plus CAD-
RADS, as shown in Supplemental Figure 1. More-
over, the model with the comprehensive CTA score
signiﬁcantly correctly reclassiﬁed patients, using risk
thresholds of <3%, 3% to 10%, and >10%, as shown by
an NRI of 12.4% (95% CI: 5.7% to 19.1%, p < 0.001).
Reclassiﬁcation data for patients with and without
events are included in Supplemental Tables 1a and 1b.
INTERNAL AND EXTERNAL VALIDATION OF THE
COMPREHENSIVE CTA SCORE. In the external vali-
dation cohort, 1,096 (55.6%) patients had a score of
0 to 5, whereas 746 (37.8%) patients had a score of 6
to 20, and 129 (6.6%) patients had a score >20. The
primary endpoint occurred in 254 patients. Supple-
mental Figure 2 shows the receiver operating char-
acteristics curves for the internal validation (training
sample: 70% of the patients, and validation sample:30% of the patients) of the derivation cohort (Leiden,
The Netherlands) and the external validation of the
comprehensive CTA score within the external vali-
dation cohort (CONFIRM registry). The c-index of the
training sample (derivation cohort), using a model
containing clinical characteristics and the compre-
hensive CTA score was 0.749; the c-index of the
validation sample was 0.789. In the external valida-
tion cohort, the c-index of this model was 0.718
(95% CI: 0.682 to 0.744), signiﬁcantly higher than the
clinical model (0.689, p < 0.001).
Figure 3 depicts the 5-year event-free survival
curves of the derivation cohort and the external
validation cohort showing a similar discriminatory
ability of the comprehensive CTA score in both
cohorts. The 5-year event-free survival for patients
with the comprehensive CTA score of 0 to 5 was
97.4%; 89.3% for a score 6 to 20, and 80.8% for
the highest score category (>20) in the derivation
cohort. In the external validation cohort, event-free
survival was 93.8% for a score 0 to 5, 83.1% for a
score 6 to 20, and 74.3% for a score >20.
DISCUSSION
The current study has shown the improved prog-
nostic signiﬁcance of a comprehensive CTA score
incorporating multiple aspects of plaque detected by
coronary CTA (plaque extent, severity, location, and
composition) to predict major clinical outcomes.
FIGURE 3 External Prognostic Validation (CONFIRM Registry) of the Comprehensive CTA Score
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Comparison of 5-years cumulative event-free survival among the derivation and external validation cohort of the comprehensive CTA score showing similar
discriminatory ability of the score. Abbreviations as in Figures 1 and 2.
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1994Compared with the CAD-RADS, our new comprehen-
sive score provided improved prediction of outcomes
and reclassiﬁcation of risk for future events. We
further evaluated the signiﬁcance of this compre-
hensive CTA score by establishing its ability to accu-
rately stratify risk in an external validation cohort.
Often risk scores perform suboptimal when externally
validated. However, the current validation ﬁndings
support the added prognostication with varying pla-
que characteristics to improve classiﬁcation of major
clinical outcomes.
PROGNOSTIC VALUE OF PLAQUE EXTENT, LOCATION,
AND COMPOSITION. The CAD-RADS provides the cur-
rent recommendations for coronary CTA reading (22).
The majority of studies assessing the prognostic
value of coronary CTA have used a stenosis severity-
focused approach, which is the major component of
the CAD-RADS. Patients without CAD have the lowest
rate of major cardiovascular events with increasing
clinical risk-adjusted HRs for nonobstructive CAD
(ranging from 1.2 to 1.6) and obstructive CAD
(ranging from 2.3 to 2.6) (23,24). The importance of
nonobstructive CAD on coronary CTA has been
addressed recently because the majority of patients
who will experience have <50% stenosis (25).
Although this approach permits risk stratiﬁcation, itdoes not take full advantage of all information on
coronary atherosclerosis that can be derived from
coronary CTA. As a result, this method may consid-
erably overestimate or underestimate the risk of
events in both patients with obstructive and non-
obstructive CAD, indicating the need for a more
detailed, patient-tailored approach (ﬁtting the new
concept of precision medicine). Prognostic value of
several plaque measures has been reported in indi-
vidual studies (2,4,5,7,9), including number of seg-
ments with obstructive CAD (7,12), plaque
composition (7), and the location of plaque in the
coronary tree (5). Because all parameters have
prognostic value, the current study aimed to bring
all these CTA parameters together and integrate
them into a comprehensive risk score.
COMPREHENSIVE CTA SCORE. The comprehensive
CTA score categories of 0 to 5, 6 to 20, and >20 pro-
vided better discrimination and correct reclassiﬁca-
tion compared with risk groups based on stenosis
severity only; event rates in the lowest category of
both scores were similarly low. However, the 3
groups of both scores include different CAD extent.
For instance, a patient with 2 obstructive calciﬁed
lesions in the ﬁrst diagonal and mid–right coro-
nary artery would have been classiﬁed in the
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 1 2 , N O . 1 0 , 2 0 1 9 van Rosendael et al.
O C T O B E R 2 0 1 9 : 1 9 8 7 – 9 7 Conventional Versus Comprehensive CTA Score
1995intermediate-/highest-risk group using the CAD-
RADS but lowest according to the new comprehen-
sive score. These ﬁndings support the hypothesis
that a comprehensive approach to grade the severity
of coronary atherosclerosis, instead of the classiﬁca-
tion based on the highest-grade stenosis, may
improve risk stratiﬁcation. This corresponds to pre-
vious observations that stenosis severity only plays a
minor role in predicting plaque rupture and a sig-
niﬁcant proportion of acute MIs occur at sites with
mild stenosis (25,26). Using coronary CTA, previous
studies have shown that integration of several plaque
measures increase risk prediction. The CONFIRM
score incorporated clinical risk parameters and the
presence of nonobstructive proximal-mixed or calci-
ﬁed plaques and proximal obstructive stenosis which
increased predictive value over clinical scores (27).
Mushtaq et al. (8) showed that the CT-Leaman score,
integrating stenosis severity with the number and
location of stenoses, was more strongly predictive of
the segment involvement score (the total number of
segments with plaque) or the segment stenosis score
(obtained by grading the stenosis severity of each
segment with plaque). The current study adds further
to the existing literature by separating 3 risk groups
which showed similar good discrimination of events
in an external validation cohort, indicating its
robustness. To be used in clinical practice, a risk
score must be easy to use, include a limited number
of variables, and be accurate. The current score ﬁts
this deﬁnition, and is based on location, composition,
and stenosis severity in the classical 17-segment
model. Previously, prognostic angiographic risk
scores have been developed in patients who under-
went invasive coronary angiography, such as the
Leaman score (15). The CAD prognostic index was
described by Mark et al. (28), which integrates in-
formation on lesion location, severity, and number of
coronary arteries involved. These scores were ob-
tained in patients undergoing clinically indicated
invasive coronary angiography, are derived from
higher-risk cohorts, and may not be optimal for the
lower-risk patients undergoing coronary CTA.
CLINICAL IMPLICATIONS. It is currently not clear
which extent of coronary atherosclerosis warrants the
initiation or intensiﬁcation of lipid-lowering therapy
and the need for using aspirin. No randomized
controlled trials have been performed to evaluate the
beneﬁt of treatment of coronary atherosclerosis based
on coronary CTA ﬁndings. But previous observations
have shown that the detection of atherosclerosis
increased the prescription of medical therapy. In astudy by Cheezum et al. (29), statin therapy was
started or intensiﬁed in 46% of patients after the
detection of nonobstructive or obstructive CAD,
which was associated with signiﬁcant reductions in
plasma cholesterol levels. Furthermore, blood pres-
sure therapy was intensiﬁed in patients with non-
obstructive and obstructive CAD in 21% and 24% of
patients, respectively; likewise, aspirin was started in
29% and 40% of patients, respectively. The CAD-
RADS signiﬁcantly improves risk prediction over
clinical variables and permits risk assessment. How-
ever, this scoring system does not perfectly “pheno-
type” the individual patient with respect to the total
coronary atherosclerotic burden in terms of plaque
extent, location, and composition. The new score may
be used to tailor medical treatment to the individual
patient by maximizing therapy for patients in the
highest risk group: targeting of very low cholesterol
levels and optimizing blood pressure, and possibly
reduce therapy for patients in the lowest risk group to
minimize side effects of medication. Future studies
should investigate whether clinical outcomes can be
improved by the clinical application of this approach
of personalizing risk stratiﬁcation.
STUDY LIMITATIONS. The observational design of
the study is a limitation; lifestyle changes, medical
therapy, and revascularization after coronary CTA
might have inﬂuenced outcome in the current cohort,
but this limitation relates to all large registries. A
direct comparison between the performances of the
new comprehensive CTA risk score and the original
CAD-RADS (including high-risk plaque features)
could not be performed (because high risk plaque
features were not systematically assessed) and
remains to be evaluated. Patients in the derivation
and validation cohort did not have similar cardio-
vascular risk proﬁles: patients in the external vali-
dation cohort were older and had more risk factors.
This may clarify the higher event rates across the 3
risk categories for the validation cohort. Generaliz-
ability of the current study may be reduced by the
lack of an independent core laboratory analysis or
clinical event committee. Also, calculation of the new
comprehensive score is more complex than the CAD-
RADS; however, automated score calculation is
feasible. The new comprehensive CTA score does not
incorporate functional stenosis information, which
can be derived with fractional ﬂow reserve-CT.
Future research should investigate the potential
added value of this technique. Finally, a large number
of patients in the external validation cohort were
excluded which may have introduced selection bias.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
A novel comprehensive CTA score based on the
extent, severity, location, and composition of CAD
incorporates all aspects of coronary atherosclerosis
into 1 per patient score and provides superior risk
stratiﬁcation then a score based on stenosis severity
only.
TRANSLATIONAL OUTLOOK: A holistic approach
to classify CAD improves the estimation of a patient’s
risk for future cardiovascular events which may
translate into more accurate post-CTA medical care
and improved cardiovascular outcome.
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1996CONCLUSIONS
The CTA risk score incorporating coronary plaque
extent, location, severity, and composition improved
prediction of events compared with the CAD-RADS
based on stenosis severity. Moreover, the model
retained good prognostic accuracy in an external
validation cohort. The proposed model allows precise
prediction of future events and may help further
guide risk stratiﬁcation.
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